Succinate dehydrogenase, a well-characterized enzyme complex serving dual roles in the tricarboxylic acid (TCA) cycle and the mitochondrial respiratory chain, has long been a subject of intense interest. Its loss or mutation has been implicated in various cancers, especially those associated with hereditary paragangliomas and pheochromocytomas. The current study, however, shifts focus onto the biochemical consequences arising from SDH loss that extend beyond mitochondrial dysfunction, illuminating its influence on nucleotide biosynthesis—a cornerstone for cellular proliferation.

The research team demonstrated that depletion of SDH leads to an intracellular accumulation of succinate. While succinate’s role as an oncometabolite, capable of modulating epigenetic landscapes through competitive inhibition of α-ketoglutarate-dependent dioxygenases, is well documented, this investigation highlights a distinct metabolic function. Succinate was found to directly inhibit ATCase, an enzyme catalyzing the condensation of carbamoyl phosphate and aspartate into carbamoyl aspartate, a pivotal step in the pyrimidine synthesis pathway.

Pyrimidine nucleotides, vital for DNA and RNA synthesis, must be tightly regulated to meet cellular demands, especially in rapidly dividing cells such as tumors. By impairing ATCase activity, succinate accumulation effectively throttles the supply of pyrimidine precursors, thereby exerting a suppressive effect on nucleotide biosynthesis. This metabolite-enzyme interaction reveals a previously underappreciated metabolic checkpoint governed by mitochondrial signal states.

Methodologically, the researchers employed a combination of genetic knockdown models, metabolomic profiling, and enzymatic assays to dissect the cascade triggered by SDH loss. These approaches illuminated not only the increase in succinate levels but also the subsequent restoration of pyrimidine biosynthesis upon pharmacological or genetic attenuation of succinate’s inhibitory effect on ATCase. This feedback loop provides compelling evidence for a metabolic nexus connecting mitochondrial dysfunction and nucleotide metabolism.

The implications of these findings extend into the realm of oncology, where metabolic reprogramming is a hallmark of cancer progression. The suppression of pyrimidine biosynthesis via succinate-mediated ATCase inhibition may contribute to replication stress or DNA damage responses, thereby influencing tumor cell survival and proliferation. Intriguingly, this mechanism could also explain the paradoxical growth arrest observed in some SDH-deficient tumors, challenging prevailing models that attribute oncogenicity solely to metabolic hyperactivation.

Furthermore, this work prompts reconsideration of therapeutics targeting metabolic enzymes. Drugs that modulate succinate levels, or directly influence the activity of ATCase, could potentiate antineoplastic strategies by exploiting the vulnerabilities uncovered in SDH-deficient metabolic contexts. It also suggests that metabolic profiling of succinate and pyrimidine intermediates might serve as biomarkers for tumor classification or treatment response monitoring.

Beyond oncology, the study sheds light on fundamental cellular physiology. The dual functionality of SDH as a metabolic switch underlines how mitochondrial perturbations have far-reaching effects beyond energy homeostasis. By delineating the biochemical crosstalk between the TCA cycle and nucleotide synthesis, the authors chart new conceptual territory in metabolic regulation, hinting at similar mechanisms that might operate in diverse physiological or pathological settings.

Significantly, the research underscores the importance of enzyme-substrate interactions in metabolic control. The allosteric inhibition of ATCase by succinate exemplifies how metabolite accumulation can serve both as a signaling molecule and a direct regulator of enzymatic pathways. This paradigm inspires deeper interrogation into other metabolite-enzyme pairs that may govern cellular states in health and disease.

The study also raises provocative questions regarding metabolic compensation and adaptation. How cells negotiate the buildup of succinate and the concomitant suppression of pyrimidine synthesis could determine their fate under stress or oncogenic transformation. Future research may focus on unraveling adaptive responses that override or circumvent these metabolic blocks, potentially revealing novel drug targets or resistance mechanisms.

Moreover, the authors highlight the technical sophistication of their approach, combining high-resolution metabolomics with structural and kinetic analyses. Such integrative strategies are critical for unraveling complex metabolic interdependencies, moving beyond simple correlations to mechanistic clarity. This investigative rigor enhances confidence in the biological significance of the findings and sets a new standard for metabolic research.

In summary, this pioneering work redefines the metabolic landscape associated with SDH loss by uncovering a functional link between mitochondrial dysfunction and nucleotide synthesis inhibition. The discovery that succinate directly impedes ATCase activity to suppress pyrimidine biosynthesis not only enriches our comprehension of cellular metabolism but also holds transformative potential for therapeutic innovation in cancer and beyond. As the scientific community digests these insights, new paradigms for targeting metabolic vulnerabilities are poised to emerge.

The study exemplifies the power of integrative metabolic research to reveal unexpected regulatory circuits within the cell. By melding biochemical, genetic, and metabolic data, the investigators have elucidated a nuanced mechanism through which a classic mitochondrial enzyme influences fundamental anabolic pathways. This work will undoubtedly catalyze further investigations into metabolite-driven regulation and its implications for disease.

Looking forward, the research invites exploration into the broader landscape of TCA cycle metabolites as modulators of enzymatic networks. Understanding how other metabolites might exert similar regulatory roles could recalibrate current models of metabolic control and inspire novel therapeutic approaches for metabolic diseases and cancer.

This research not only advances our grasp of cellular metabolism but also underscores the intricate connectivity between mitochondrial function and biosynthetic pathways essential for cell proliferation. The identification of succinate as a potent inhibitor of pyrimidine biosynthesis via ATCase reveals a compelling metabolic checkpoint that may be exploited to selectively target SDH-deficient tumors.

In conclusion, the revelation that SDH loss leads to succinate accumulation which in turn suppresses pyrimidine biosynthesis through the inhibition of ATCase marks a significant leap in cancer metabolism research. These findings illuminate a complex interplay of metabolic pathways that could reshape therapeutic strategies, offering hope for more effective treatments by harnessing metabolic vulnerabilities inherent in tumor biology.

Subject of Research: Metabolic regulation of pyrimidine biosynthesis following succinate dehydrogenase loss

Article Title: Succinate dehydrogenase loss suppresses pyrimidine biosynthesis via succinate-mediated inhibition of aspartate transcarbamylase

Article References:
Hart, M.L., Sokolov, D., Danquah, S. et al. Succinate dehydrogenase loss suppresses pyrimidine biosynthesis via succinate-mediated inhibition of aspartate transcarbamylase. Nat Metab (2026). https://doi.org/10.1038/s42255-026-01524-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-026-01524-w

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, and despite advances in treatment modalities, effective targeted therapies are still urgently sought. Central to cancer cell survival and rapid proliferation is the increased demand for glucose, a primary energy source. GLUT1, a transmembrane protein facilitating glucose uptake, is notoriously upregulated in many cancers, including CRC, driving enhanced glycolytic metabolism, often referred to as the "Warburg effect." Targeting GLUT1, therefore, has emerged as a logical strategy to deprive tumor cells of their metabolic fuel.

The investigative team employed multiple human colorectal cancer cell lines, including HCT116, DLD1, COLO205, LoVo, and Caco-2, to dissect the anti-proliferative effects of BAY-876. Their in vitro experiments demonstrated that BAY-876 treatment caused a marked inhibition of cell proliferation in several cell lines, suggesting broad efficacy across different CRC subtypes. Notably, GLUT1 protein expression levels declined significantly following treatment, corroborating the drug’s intended mechanism of action.

Delving deeper into the metabolic consequences of GLUT1 inhibition, the researchers conducted flux analyses to monitor changes in cellular respiration. Unexpectedly, despite glucose uptake suppression, treated cells exhibited enhanced mitochondrial respiration. This metabolic shift appeared to be a cellular attempt to compensate for diminished glycolysis. However, this upregulation of mitochondrial activity was accompanied by a surge in reactive oxygen species (ROS), toxic molecules known to inflict oxidative damage within cells.

The accumulation of ROS, precipitated by mitochondrial hyperactivity, led to an increase in apoptosis rates among the colorectal cancer cells. By inducing programmed cell death, BAY-876 effectively undermined tumor cell viability. Western blot assays reinforced these observations, revealing diminished GLUT1 expression and confirming the drug’s impact on critical metabolic pathways.

Perhaps most compelling was the in vivo validation of BAY-876’s anti-cancer potential. Through the establishment of a mouse xenograft model implanted with HCT116 CRC cells, the treatment regimen demonstrated significant tumor growth inhibition. Not only were the tumors smaller in BAY-876-treated animals, but the suppressed GLUT1 expression within these tumors underscored the drug’s targeted efficacy.

The findings of this study illuminate the intricate interplay between cancer metabolism and therapeutic intervention. By inhibiting GLUT1, BAY-876 disrupts the glucose-dependent metabolic machinery that CRC cells rely on, forcing these cells into heightened mitochondrial respiration that ultimately proves cytotoxic. This metabolic vulnerability presents a novel therapeutic window that could be exploited for more effective colorectal cancer treatments.

The research bears significant clinical implications, particularly given the often limited success of conventional chemotherapies in advanced CRC. BAY-876’s ability to selectively target metabolic pathways, alongside evidentiary support from both cellular and animal models, raises hope for a new class of metabolism-focused anti-cancer drugs.

Furthermore, the study enhances our fundamental understanding of cancer cell bioenergetics, suggesting that metabolic plasticity—while a survival advantage for tumors—can be a double-edged sword. The forced switch to mitochondrial respiration, under GLUT1 inhibition, acts as a “metabolic trap,” amplifying ROS production beyond manageable levels, triggering apoptosis.

Importantly, these discoveries open avenues for combinatorial approaches where BAY-876 might be paired with other agents that either heighten oxidative stress or further block metabolic adaptations, potentially amplifying the anti-tumor response while circumventing resistance mechanisms.

While this study focused on colorectal cancer, the implications may well extend to other GLUT1-overexpressing tumors. Prior studies have already reported BAY-876’s efficacy in ovarian and breast cancers, and this latest research adds robust data for colorectal malignancies, broadening the scope of application.

Future investigations will need to address long-term safety, optimal dosing strategies, and potential effects on normal tissues that also express GLUT1. However, the specificity of BAY-876 for cancer cells, combined with the metabolic dependence of tumors, presents a favorable therapeutic index.

This research not only highlights the therapeutic potential of GLUT1 inhibition but also exemplifies the power of targeting cancer metabolism—a burgeoning field that may revolutionize oncologic practice in the coming decades. Inhibiting metabolic pathways critical to tumor survival while sparing normal cells is an attractive paradigm demanding intense scientific focus.

In summary, BAY-876 emerges as a strong candidate for targeted colorectal cancer therapy by selectively disrupting glucose uptake, inducing lethal metabolic stress, and triggering apoptotic cell death in tumor cells. The translational promise is clear, and if clinical trials bear out these preclinical results, BAY-876 could usher in a new era of metabolism-centered cancer treatment.

As we continue to uncover the metabolic vulnerabilities of cancer cells, agents like BAY-876 epitomize the future of personalized, mechanism-based oncology. Selectively cutting off nutrient supply lines and exploiting metabolic imbalances may prove to be one of the most effective strategies yet devised to combat treatment-resistant cancers.

This insightful study underscores the critical importance of glucose metabolism in colorectal cancer progression and provides a beacon of hope for patients through innovative targeted therapies. With continued research and clinical validation, BAY-876 may soon translate from lab bench to frontline clinical use, offering a powerful new weapon against one of the world’s deadliest cancers.

Subject of Research: GLUT1 inhibition and metabolic effects in human colorectal cancer cells

Article Title: GLUT1 inhibition by BAY-876 induces metabolic changes and cell death in human colorectal cancer cells

Article References:
Hayashi, M., Nakamura, K., Harada, S. et al. GLUT1 inhibition by BAY-876 induces metabolic changes and cell death in human colorectal cancer cells. BMC Cancer 25, 716 (2025). https://doi.org/10.1186/s12885-025-14141-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14141-9